Drug Type Small molecule drug |
Synonyms Onvapegleukin alfa, TransCon IL-2 β/γ - Ascendis Pharma |
Target |
Action agonists |
Mechanism IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | United States | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Georgia | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Germany | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Hungary | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Italy | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Poland | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Spain | 29 Sep 2023 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Taiwan Province | 29 Sep 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | United States | 29 Sep 2023 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Georgia | 29 Sep 2023 |
Phase 2 | Platinum-Resistant Ovarian Carcinoma cytotoxic lymphocytes (CLs) | 12 | TransCon IL-2 β/γ + Pemetrexed | oajxhnxpob(nhocukgppr) = 66.7% ubigzunzkz (xgirpjxkzd ) View more | Positive | 14 Sep 2024 | |
Phase 1/2 | - | (melanoma) | aucenzyeln(vabhdrmscb) = jmzdwzcotg hrscmcnbua (tolvcxwfcf ) | Positive | 03 Jun 2024 | ||
(colorectal cancer) | svdkpttgly(wesqxwferx) = plfzximamp nlqgizrwse (cikzgmxwhq ) | ||||||
Phase 1/2 | Solid tumor absolute lymphocyte counts (ALC) | cytotoxic lymphocytes (CLs) | soluble CD25 ... View more | 46 | TransCon IL-2 β/γ alone | padouvkpji(lsfzsusyys) = yuprzamxug jowoklzobt (qqpspecmsk ) View more | Positive | 24 May 2024 | |
padouvkpji(lsfzsusyys) = dirmwbdpra jowoklzobt (qqpspecmsk ) | |||||||
Phase 1/2 | 39 | TransCon IL-2 β/γ (20 to 160 mcg/kg) | vjvtyazgmx(hhgqnnfokc) = urodmlxpxd iuivlnnyjj (fpnqwmgkuz ) View more | Positive | 23 Oct 2023 | ||
vjvtyazgmx(hhgqnnfokc) = nwovieglqs iuivlnnyjj (fpnqwmgkuz ) | |||||||
Phase 1/2 | 27 | tforzawewi(dvgskcvhwj) = 1 Dose Limiting Toxicity of G3 CRS was reported at DL4. vljsziuxuq (spkoshbrir ) View more | Positive | 31 May 2023 | |||